CVS HEALTH Corp
—- Market cap
- —
- Debt
- +$64.57B
- Cash
- −$8.45B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CVS stock price vs TEAM: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at TEAM's multiple
Needs TEAM P/E.
Implied fair value · at CVS's multiple
Needs Annual EPS, CVS P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
17 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CVS HEALTH Corp · implied price per share
Bear
$43.35
Base
$58.49
Bull
$78.21
Atlassian Corporation · implied price per share
The ordinary-share to listed-security ratio could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Walgreens Boots Alliance, Inc.
CVS vs WBA
UNITEDHEALTH GROUP INC
CVS vs UNH
Walmart Inc.
CVS vs WMT
Cigna Group
CVS vs CI
HUMANA INC
CVS vs HUM
Elevance Health, Inc.
CVS vs ELV
MICROSOFT CORP
CVS vs MSFT
ADOBE INC.
CVS vs ADBE
Salesforce, Inc.
CVS vs CRM
ORACLE CORP
CVS vs ORCL
DOCUSIGN, INC.
CVS vs DOCU
BOX INC
CVS vs BOX
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CVS can sustain its current profitability and avoid margin compression while trading near its historical band, then holding or modestly adding makes more sense than chasing the TEAM-based TEAM multiple, because the valuation gap is driven by non-comparable multiple expansion rather than by CVS’s own trading history.
On a P/S basis, CVS at 0.3x is dramatically cheaper than TEAM at 7.3x, which mechanically explains the very large implied-price gap. However, TEAM-implied valuation range is driven by TEAM’s software-style multiple, so applying it to CVS creates an extreme and likely non-comparable result rather than a clean upside signal.
Supporting Metrics